Department of Family Medicine, St. Martin De Porres Hospital, Chiayi, Taiwan, ROC.
Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
J Chin Med Assoc. 2020 Oct;83(10):967-971. doi: 10.1097/JCMA.0000000000000384.
The current Western medicine treatment options for benign prostatic hyperplasia (BPH) have various degrees of documented effectiveness. However, the uses of these interventions are limited to specific patient populations or have certain side effects that interfere with patient quality of life. This study evaluated the clinical effects of a Chinese herbal medicine (CHM) on patients with BPH.
This was a single-arm pilot study. Twenty BPH patients were enrolled, and they were required to take the investigated CHM three times a day for 8 weeks, along with their Western medicine. Patients returned to clinics as scheduled and completing international prostate symptoms scores (IPSS), aging male symptoms score, international index of erectile function, and body constitution questionnaire of traditional Chinese medicine. Uroflowmetry and sonography were also applied to evaluate the changes in urinary velocity and post-voiding residual urine volume from the baseline to the end of the study.
The mean IPSS total score was significantly decreased by 2.5 points after 8 weeks of treatment with the CHM (from 17.5 to 15.0, p = 0.03). The mean IPSS voiding subscore was decreased by 1.7 points (from 10.1 to 8.4, p = 0.02), and the mean incomplete emptying subscore was decreased by 0.8 points (from 2.9 to 2.1, p = 0.02), with both decreases being statistically significant. A descending trend in the post-voiding residual urine volume was also observed (from 52.9 to 30.8 mL, p = 0.07).
This trial indicated that the add-on CHM treatment (VGHBPH0) might be a potential treatment for improving the lower urinary tract symptoms of BPH patients.
目前,西医治疗良性前列腺增生(BPH)的方法有不同程度的有效性记录。然而,这些干预措施的使用仅限于特定的患者群体,或者有某些副作用会干扰患者的生活质量。本研究评估了一种中药(CHM)对 BPH 患者的临床疗效。
这是一项单臂试点研究。共纳入 20 例 BPH 患者,要求他们每天服用 3 次研究中的 CHM,同时服用西药。患者按计划返回诊所,完成国际前列腺症状评分(IPSS)、男性衰老症状评分、国际勃起功能指数和中医体质问卷。还应用尿流率和超声检查评估从基线到研究结束时尿流速和残余尿量的变化。
服用 CHM 8 周后,IPSS 总分平均下降 2.5 分(从 17.5 降至 15.0,p = 0.03)。IPSS 排尿症状评分平均下降 1.7 分(从 10.1 降至 8.4,p = 0.02),不完全排空症状评分平均下降 0.8 分(从 2.9 降至 2.1,p = 0.02),两者均有统计学意义。残余尿量也呈下降趋势(从 52.9 降至 30.8mL,p = 0.07)。
本试验表明,附加 CHM 治疗(VGHBPH0)可能是改善 BPH 患者下尿路症状的潜在治疗方法。